Cryoport(US:CYRX)2025-11-04 22:18Revenue Growth - Q3 2025 revenue increased 15% year-over-year to $44.2 million, with Life Sciences Services revenue growing 16% to $24.3 million[5] - Revenue from commercial cell and gene therapies rose 36% year-over-year to $8.3 million, contributing to the overall revenue growth[3] - Life Sciences Products revenue grew 15% year-over-year to $20.0 million, representing 45% of total revenue from continuing operations[22] - Total revenue for Q3 2025 was $44.233 million, a 15.1% increase from $38.317 million in Q3 2024[38] - Life Sciences Services revenue reached $24.258 million, up 15.6% from $20.931 million year-over-year[38] - Life Sciences Products revenue increased to $19.975 million, representing a 15.1% growth compared to $17.386 million in the same quarter last year[38] Financial Performance - The company reported a net loss of $6.943 million for Q3 2025, compared to a net income of $805,000 in Q3 2024[38] - Operating costs and expenses totaled $31.257 million for Q3 2025, slightly up from $30.825 million in Q3 2024[38] - The loss from operations for the nine months ended September 30, 2025, was $26.775 million, a decrease from $108.926 million for the same period in 2024[38] - For the three months ended September 30, 2025, GAAP net income was $(6,943) thousand, compared to $805 thousand for the same period in 2024[45] - Adjusted net income (loss) for the three months ended September 30, 2025, was $(6,696) thousand, compared to $(16,521) thousand in 2024[45] Guidance and Future Outlook - The company updated its full-year 2025 revenue guidance to a range of $170 million to $174 million, reflecting strong year-to-date performance[7] - The company expects to provide updated guidance for full-year 2025 revenue during the upcoming conference call[36] - Anticipated up to 25 possible BLA/MAA filings in 2026, indicating a strong pipeline for future growth[14] Cash and Assets - The company held $421.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025[26] - Current assets totaled $484.84 million, an increase from $457.72 million year-over-year[39] - Cash and cash equivalents were reported at $255.81 million, compared to $334.13 million in the previous year[39] - Total assets amounted to $774.32 million, up from $703.49 million year-over-year[39] - Current liabilities reached $307.49 million, an increase from $256.36 million in the previous year[39] Operational Highlights - Cryoport supported a total of 745 global clinical trials as of September 30, 2025, a net increase of 54 trials from the previous year[10] - The company launched next-generation dry vapor shippers with integrated condition monitoring solutions, enhancing its product offerings[4] - Cryoport is focusing on expanding its global supply chain centers and enhancing its strategic partnership with DHL[36] - The company is actively developing new products and services to meet the growing demands of the life sciences sector[36] Cost Management - Total GAAP operating costs and expenses for the three months ended September 30, 2025, were $31,257 thousand, slightly up from $30,825 thousand in 2024[44] - Non-GAAP adjusted operating costs and expenses for the nine months ended September 30, 2025, were $88,118 thousand, down from $159,089 thousand in 2024[44] - Stock-based compensation expense for the three months ended September 30, 2025, was $2,526 thousand, down from $4,056 thousand in 2024[46] Impairments and Losses - The company reported an impairment loss of $(63,809) thousand for the nine months ended September 30, 2024[45] - The company incurred acquisition and integration costs of $69 thousand for the nine months ended September 30, 2025[46] - The company experienced a foreign currency gain of $2,521 thousand for the nine months ended September 30, 2025[46]